Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1292-1302

  Kiser, Katie L ^a   Badowski, Melissa E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Acquired immunodeficiency syndrome; AIDS; CD4+ count; HIV; Human immunodeficiency virus; Opportunistic infections; Protease inhibitors; Protein C deficiency; Protein S deficiency; Venous thromboembolism; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; MEGESTROL ACETATE; NELFINAVIR; PHOSPHOLIPID ANTIBODY; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; CACHEXIA; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; DISEASE PREDISPOSITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; VIRUS LOAD;

AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPHOSPHOLIPID SYNDROME; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MODELS, BIOLOGICAL; OPPORTUNISTIC INFECTIONS; PROTEASE INHIBITORS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTORS; SEX FACTORS; VENOUS THROMBOEMBOLISM;

EID: 78650227373     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1292     Document Type: Review

References (68)

1. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals from the council on thrombosis (in consultation with the council on cardiovascular radiology) American Heart Association. Circulation 1996;93:2212-45.
2. UNAIDS, World Health Organization. AIDS epidemic update: December 2007. Available from http://data.unaids.org/pub/EPI Slides/2007/2007-epiupdate-en.pdf. Accessed June 5, 2009.
3. National Quality Forum. National voluntary consensus standards for prevention and care of venous thromboembolism: policy, preferred practice, and initial performance measures. Available from http://www.qualityforum.org/pdf/ reports/vte/VTE-Executive-Summary.pdf. Accessed June 5, 2009.
4. U.S. Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Available from http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on- dvt- 2008.pdf. Accessed June 5, 2009.
5. The Joint Commission. Accreditation program: national patient safety goals. Available from http://www.jointcommission.org/PatientSafety/ NationalPatientSafetyGoals/09-hap-npsgs.htm. Accessed June 5, 2009.
6. Copur AS, Smith PR, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002;16:205-9.
7. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133:S381-453.
8. Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008;48:310-14.
9. Callens S, Florence E, Philippe M, Van Der Planken M, Colebunders R. Mixed arterial and venous thromboembolism in a person with HIV infection. Scand J Infect Dis 2003;35:907-8.
10. Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost 2004;10:19-25.
11. Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004;39:1214-22.
12. Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals: the adult/adolescent spectrum of HIV disease project. AIDS 2000;14:321-4.
13. Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005;63:129-36.
14. George SL, Swindells S, Knudson R, Stapleton JT. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med 1999;107:624-30.
15. Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001;15:15-24.
16. Laing RB, Brettle RP, Leen CL. Venous thrombosis in HIV infection. Int J STD AIDS 1996;7:82-5.
17. Fultz SL, McGinnis KA, Skanderson M, Ragni MV, Justice AC. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004;116:420-3.
18. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006;4:1928-30.
19. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg 2001;67:645-7.
20. Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008;22:771-8.
21. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001;15:311-20.
22. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:I-9-16.
23. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-63.
24. Dillmon MS, Saag MS, Hamza SH, Adler BK, Marques MB. Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature. AIDS Res Hum Retroviruses 2005;21:753-6.
25. Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992;5:484-9.
26. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993;81:1801-7.
27. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003;9:325-31.
28. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection: the role of anticardiolipin and anti-protein S antibodies. Thromb Res 1994;73:165-75.
29. Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992;5:127-31.
30. Sugerman RW, Church JA, Goldsmith JC, Ens GE. Acquired protein S deficiency in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1996;15:106-11.
31. Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Protein S deficiency and HIV infection [letter]. N Engl J Med 1991;324:1220.
32. Feffer SE, Fox RL, Orsen MM, Harjai KJ, Glatt AE. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. South Med J 1995;88:1126-30.
33. Karpatkin S, Nardi M, Green D. Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost 2002;88:389-401.
34. Lijfering WM, Sprenger HG, Georg RR, van der Meulen PA, van der Meer J. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 2008;54:1226-33.
35. Janier M, Flageul B, Drouet L, et al. Cutaneous and plasma values of von Willebrand factor in AIDS: a marker of endothelial stimulation? J Invest Dermatol 1988;90:703-7.
36. Levine AM, Vigen C, Gravink J, Mack W, Watts CH, Liebman HA. Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr 2006;42:572-7.
37. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997;77:856-61.
38. Stimmler MM, Quismorio FP Jr, McGehee WG, Boylen T, Sharma OP. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med 1989;149:1833-5.
39. Coll Daroca J, Gutierrez-Cebollada J, Yazbeck H, Berges A, Rubies-Prat J. Anticardiolipin antibodies and acquired immunodeficiency syndrome: prognostic marker or association with HIV infection? Infection 1992;20:140-2.
40. Medina-Rodriguez F, Guzman C, Jara LJ, et al. Rheumatic manifestations in human immunodeficiency virus positive and negative individuals: a study of 2 populations with similar risk factors. J Rheumatol 1993;20:1880-4.
41. Carreno L, Monteagudo I, Lopez-Longo FJ, et al. Anticardiolipin antibodies in pediatric patients with human immunodeficiency virus. J Rheumatol 1994;21:1344-6.
42. + B cells in HIV infection. Clin Exp Immunol 1999;115:464-71.
43. Matsuda J, Gohchi K, Hama H, Tsukamoto M, Saitoh N, Kinoshita T. High prevalence of anti-cardiolipin antibody, C1q-, C3d-, and mRF-IgG immune complexes, and anti-nuclear antibody in hemophiliacs irrespective of infection with human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 1993;6:1120-4.
44. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999;13:347-55.
45. Capel P, Janssens A, Clumeck N, et al. Anticardiolipin antibodies (ACA) are most often not associated with lupus-like anticoagulant (LLAC) in human immunodeficiency virus (HIV) infection. Am J Hematol 1991;37:234-8.
46. Constans J, Guerin V, Couchouron A, et al. Autoantibodies directed against phospholipids or human beta2-glycoprotein I in HIV-seropositive patients: relationship with endothelial activation and antimalonic dialdehyde antibodies. Eur J Clin Invest 1998;28:115-22.
47. Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 2007;9:212-18.
48. Hassell KL, Kressin DC, Neumann A, Ellison R, Marlar RA. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coagul Fibrinolysis. 1994;5:455-62.
49. Cappell MS, Simon T, Tiku M. Splenic infarction associated with anticardiolipin antibodies in a patient with acquired immunodeficiency syndrome. Dig Dis Sci 1993;38:1152-5.
50. Leder AN, Flansbaum B, Zandman-Goddard G, Asherson R, Shoenfeld Y. Antiphospholipid syndrome induced by HIV. Lupus 2001;10:370-4.
51. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002;31:256-63.
52. Keeling DM, Birley H, Machin SJ. Multiple transient ischaemic attacks and a mild thrombotic stroke in a HIV-positive patient with anticardiolipin antibodies. Blood Coagul Fibrinolysis 1990;1:333-5.
53. Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986;256:491-3.
54. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997;77:856-61.
55. de Larranaga GF, Forastiero RR, Carreras LO, Alonso BS. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. Thromb Res 1999;96:19-25.
56. Pinilla J, Hill AR. Thromboembolism associated with acquired immunodeficiency syndrome [letter]. Chest 1992;102:1634.
57. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009; 1-161. Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed June 14, 2010.
58. Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:175-80.
59. Bagley PH, Scott DA, Smith LS, Schillaci RF. Cytomegalovirus infection, ascending myelitis, and pulmonary embolus [letter]. Ann Intern Med 1986;104:587.
60. Howling SJ, Shaw PJ, Miller RF. Acute pulmonary embolism in patients with HIV disease. Sex Transm Infect 1999;75:25-9.
61. Gold JE, Haubenstock A, Zalusky R. Lupus anticoagulant and AIDS. N Engl J Med 1986;314:1252-3.
62. Labarca JA, Rabaggliati RM, Radrigan FJ, et al. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. Clin Infect Dis 1997;24:197-200.
63. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep 2009;58(RR-4):1-207.
64. Jenkins RE, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. AIDS 1991;5:1540-2.
65. van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992;68:364-70.
66. Aboulafia DM, Bundow D, Waide S, Bennet C, Kerr D. Initial observations on the efficacy of highly active antiretroviral therapy in the treatment of HIV-associated autoimmune thrombocytopenia. Am J Med Sci 2000;320:117-23.
67. Louw S, Jacobson BF, Buller H. Human immunodeficiency virus infection and acute deep vein thromboses. Clin Appl Thromb Hemost 2008;14:352-5.
68. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002;106:1420-5.